Mineralocorticoid receptor antagonists - Pharmacodynamics and pharmacokinetic differences

Current Opinion in Pharmacology

Volumn 27, Issue , 2016, Pages 78-85

  Yang, Jun ^a,b   Young, Morag J ^a,b  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOXAZIN 3 ONE DERIVATIVE; CS 3150; DSR 71167; EPLERENONE; FINERENONE; LY 2623091; MINERALOCORTICOID ANTAGONIST; MT 3995; OXAZOLIDINEDIONE DERIVATIVE; PF 03882845; R 14C; SM 368229; SPIRONOLACTONE; UNCLASSIFIED DRUG; ALDOSTERONE;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STABILITY; HUMAN; IC50; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANALOGS AND DERIVATIVES; ANIMAL; CLINICAL TRIAL (TOPIC); HEART FAILURE;

ALDOSTERONE; ANIMALS; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; SPIRONOLACTONE;

EID: 84959331256     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2016.02.005     Document Type: Review

References (63)

1. C.M. Kagawa, F.M. Sturtevant, and C.G. Van Arman Pharmacology of a new steroid that blocks salt activity of aldosterone and desoxycorticosterone J Pharmacol Exp Therap 126 1959 123 130
2. S.M. Garthwaite, and E.G. McMahon The evolution of aldosterone antagonists Mol Cell Endocrinol 217 2004 27 31
3. J. Fagart, J.M. Wurtz, A. Souque, C. Hellal-Levy, D. Moras, and M.E. Rafestin-Oblin Antagonism in the human mineralocorticoid receptor Embo J 17 1998 3317 3325
4. B. Couette, M. Lombes, E.E. Baulieu, and M.E. Rafestin-Oblin Aldosterone antagonists destabilize the mineralocorticosteroid receptor Biochem J 282 1992 697 702
5. D.J. Greenblatt, and J. Koch-Weser Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program JAMA 225 1973 40 43
6. J.W. Funder, D. Feldman, E. Highland, and I.S. Edelman Molecular modifications of anti-aldosterone compounds: effects on affinity of spirolactones for renal aldosterone receptors Biochem Pharmacol 23 1974 1493 1501
7. M. de Gasparo, U. Joss, H.P. Ramjoué, S.E. Whitebread, H. Haenni, L. Schenkel, C. Kraehenbuehl, M. Biollaz, J. Grob, and J. Schmidlin Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro J Pharmacol Exp Therap 240 1987 650 656
8. F.M. Rogerson, Y. Yao, B.J. Smith, and P.J. Fuller Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor Clin Exp Pharmacol Physiol 31 2004 704 709
9. X. Hu, S. Li, E.G. McMahon, D.S. Lala, and A.E. Rudolph Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone Mini Rev Med Chem 5 2005 709 718
10. P. Kolkhof, and S.A. Borden Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics Mol Cell Endocrinol 350 2012 310 317
11. C.S. Cook, L.M. Berry, R.H. Bible, J.D. Hribar, E. Hajdu, and N.W. Liu Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans Drug Metab Dispos 31 2003 1448 1455
12. C.G. Brilla, and K.T. Weber Mineralocorticoid excess, dietary sodium, and myocardial fibrosis J Lab Clin Med 120 1992 893 901
13. H. Selye Protection by a steroid-spirolactone against certain types of cardiac necroses Proc Soc Exp Biol Med 104 1960 212 213
14. M. Young, and J.W. Funder Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treated rats Endocrinology 145 2004 3153 3157
15. G. Suzuki, H. Morita, T. Mishima, V.G. Sharov, A. Todor, E.J. Tanhehco, A.E. Rudolph, E.G. McMahon, S. Goldstein, and H.N. Sabbah Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure Circulation 106 2002 2967 2972
16. B. Pitt, F. Zannad, W.J. Remme, R. Cody, A. Castaigne, A. Perez, J. Palensky, J. Wittes, and The Randomized Aldactone Evaluation Study I The effect of spironolactone on morbidity and mortality in patients with severe heart failure N Engl J Med 341 1999 709 717
17. B. Pitt, W. Remme, F. Zannad, J. Neaton, F. Martinez, B. Roniker, R. Bittman, S. Hurley, J. Kleiman, M. Gatlin, and et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 2003 1309 1321
18. F. Zannad, J.J.V. McMurray, H. Krum, D.J. van Veldhuisen, K. Swedberg, H. Shi, J. Vincent, S.J. Pocock, and B. Pitt Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 2010 11 21
19. B. Pitt, N. Reichek, R. Willenbrock, F. Zannad, R.A. Phillips, B. Roniker, J. Kleiman, S. Krause, D. Burns, and G.H. Williams Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study Circulation 108 2003 1831 1838
20. F. Edelmann, R. Wachter, A.G. Schmidt, and et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the aldo-dhf randomized controlled trial JAMA 309 2013 781 791
21. H.V. Joffe, R.Y. Kwong, M.D. Gerhard-Herman, C. Rice, K. Feldman, and G.K. Adler Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus J Clin Endocrinol Metab 92 2007 2552 2558
22. C. Zwadlo, and J. Bauersachs Mineralocorticoid receptor antagonists for therapy of coronary artery disease and related complications Curr Opin Pharmacol 13 2013 280 286
23. J. Bauersachs, F. Jaisser, and R. Toto Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases Hypertension 65 2015 257 263
24. M. Zhao, I. Célérier, E. Bousquet, J.-C. Jeanny, L. Jonet, M. Savoldelli, O. Offret, A. Curan, N. Farman, F. Jaisser, and et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy J Clin Investig 122 2012 2672 2679
25. R.P. Singh, J.E. Sears, R. Bedi, A.P. Schachat, J.P. Ehlers, and P.K. Kaiser Oral eplerenone for the management of chronic central serous chorioretinopathy Int J Ophthalmol 8 2015 310 314
26. J.A. Chadwick, J.S. Hauck, J. Lowe, J.J. Shaw, D.C. Guttridge, C.E. Gomez-Sanchez, E.P. Gomez-Sanchez, and J.A. Rafael-Fortney Mineralocorticoid receptors are present in skeletal muscle and represent a potential therapeutic target Faseb J 29 2015 4544 4554
27. P. Rossignol, D. Dobre, J.J.V. McMurray, K. Swedberg, H. Krum, D.J. van Veldhuisen, H. Shi, M. Messig, J. Vincent, N. Girerd, and et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the eplerenone in mild patients hospitalization and survival study in heart failure (EMPHASIS-HF) Circ Heart Failure 7 2014 51 58
28. O. Vardeny, B. Claggett, I. Anand, P. Rossignol, A.S. Desai, F. Zannad, B. Pitt, and S.D. Solomon Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist Circ Heart Failure 7 2014 573 579
29. P. Kolkhof, C. Nowack, and F. Eitner Nonsteroidal antagonists of the mineralocorticoid receptor Curr Opin Nephrol Hypertens 24 2015 417 424
30. S. Orena, T.S. Maurer, L. She, R. Eudy, V. Bernardo, D. Dash, P. Loria, M.E. Banker, M. Tugnait, C.V. Okerberg, and et al. PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy Front Pharmacol 4 2013 115
31. T. Nariai, K. Fujita, K. Kawane, M. Mori, R. Nakayama, K. Matsuda, S. Katayama, N. Fukuda, S. Hori, M. Iwata, and et al. DSR-71167, a novel mineralocorticoid receptor antagonist with carbonic anhydrase inhibitory activity, separates urinary sodium excretion and serum potassium elevation in rats J Pharmacol Exp Therap 354 2015 2 9
32. K. Arai, T. Homma, Y. Morikawa, N. Ubukata, H. Tsuruoka, K. Aoki, H. Ishikawa, M. Mizuno, and T. Sada Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist Eur J Pharmacol 761 2015 226 234
33. L. Bärfacker, A. Kuhl, A. Hillisch, R. Grosser, S. Figueroa-Pérez, H. Heckroth, A. Nitsche, J.-K. Ergüden, H. Gielen-Haertwig, K.-H. Schlemmer, and et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases ChemMedChem 7 2012 1385 1403
34. G.B. Arhancet, S.S. Woodard, K. Iyanar, B.L. Case, R. Woerndle, J.D. Dietz, D.J. Garland, J.T. Collins, M.A. Payne, J.R. Blinn, and et al. Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists J Med Chem 53 2010 5970 5978
35. H. Kosaka, K. Hirayama, N. Yoda, K. Sasaki, T. Kitayama, H. Kusaka, and M. Matsubara The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family Eur J Pharmacol 635 2010 49 55
36. T. Matsui, M. Takeuchi, and S-i. Yamagishi Nifedipine, a calcium channel blocker, inhibits inflammatory and fibrogenic gene expressions in advanced glycation end product (AGE)-exposed fibroblasts via mineralocorticoid receptor antagonistic activity Biochem Biophys Res Commun 396 2010 566 570
37. J.D. Dietz, S. Du, C.W. Bolten, M.A. Payne, C. Xia, J.R. Blinn, J.W. Funder, and X. Hu A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity Hypertension 51 2008 742 748
38. L. Amazit, F. Le Billan, P. Kolkhof, K. Lamribet, S. Viengchareun, M.R. Fay, J.A. Khan, A. Hillisch, M. Lombes, M.E. Rafestin-Oblin, and et al. Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1 J Biol Chem 290 2015 21876 21889
39. C. Massaad, M. Lombes, M. Aggerbeck, M.E. Rafestin-Oblin, and R. Barouki Cell-specific, promoter-dependent mineralocorticoid agonist activity of spironolactone Mol Pharmacol 51 1997 285 292
40. P. Kolkhof, M. Delbeck, A. Kretschmer, W. Steinke, E. Hartmann, L. Barfacker, F. Eitner, B. Albrecht-Kupper, and S. Schafer Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury J Cardiovasc Pharmacol 64 2014 69 78
41. B. Pitt, L. Kober, P. Ponikowski, M. Gheorghiade, G. Filippatos, H. Krum, C. Nowack, P. Kolkhof, S.Y. Kim, and F. Zannad Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial Eur Heart J 34 2013 2453 2463
42. G.L. Bakris, R. Agarwal, J.C. Chan, and et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial JAMA 314 2015 884 894
43. R. Alzamora, L. Michea, and E.T. Marusic Role of 11{beta}-hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human arteries Hypertension 35 2000 1099 1104
44. A.S. Mihailidou, M. Mardini, and J.W. Funder Rapid, nongenomic effects of aldosterone in the heart mediated by {epsilon} protein kinase C Endocrinology 145 2004 773 780
45. 2+ levels, and vasoconstriction in mesenteric resistance vessels Endocrinology 146 2005 973 980
46. A.W. Ashton, T.Y.L. Le, C.E. Gomez-Sanchez, M.-C. Morel-Kopp, B. McWhinney, A. Hudson, and A.S. Mihailidou Role of nongenomic signaling pathways activated by aldosterone during cardiac reperfusion injury Mol Endocrinol 29 2015 1144 1155
47. M.L. Hultman, N.V. Krasnoperova, S. Li, S. Du, C. Xia, J.D. Dietz, D.S. Lala, D.J. Welsch, and X. Hu The ligand-dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms Mol Endocrinol 19 2005 1460 1473
48. J. Fagart, A. Hillisch, J. Huyet, L. Barfacker, M. Fay, U. Pleiss, E. Pook, S. Schafer, M.-E. Rafestin-Oblin, and P. Kolkhof A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule J Biol Chem 285 2010 29932 29940
49. J. Yang, C-y Chang, R. Safi, J. Morgan, D.P. McDonnell, P.J. Fuller, C.D. Clyne, and M.J. Young Identification of ligand-selective peptide antagonists of the mineralocorticoid receptor using phage display Mol Endocrinol 25 2011 32 43
50. J. Yang, P.J. Fuller, J. Morgan, H. Shibata, D.P. McDonnell, C.D. Clyne, and M.J. Young Use of phage display to identify novel mineralocorticoid receptor-interacting proteins Mol Endocrinol 28 2014 1571 1584
51. B.R. Everaert, G.A. Boulet, J.-P. Timmermans, and C.J. Vrints Importance of suitable reference gene selection for quantitative real-time PCR: special reference to mouse myocardial infarction studies PLoS ONE 6 2011 e23793
52. M. Collin, F. Niemann, and F. Jaisser Mineralocorticoid receptor modulators: a patent review (2007-2012) Expert Opin Therap Patents 24 2014 177 183
53. + excretion activity J Pharmacol Sci 115 2011 346 353
54. A. Casimiro-Garcia, D.W. Piotrowski, C. Ambler, G.B. Arhancet, M.E. Banker, T. Banks, C.M. Boustany-Kari, C. Cai, X. Chen, R. Eudy, and et al. Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-me thoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist J Med Chem 57 2014 4273 4288
55. T. Hasui, N. Matsunaga, T. Ora, N. Ohyabu, N. Nishigaki, Y. Imura, Y. Igata, H. Matsui, T. Motoyaji, T. Tanaka, and et al. Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists J Med Chem 54 2011 8616 8631
56. N. Takamura, T. Maruyama, S. Ahmed, A. Suenaga, and M. Otagiri Interactions of aldosterone antagonist diuretics with human serum proteins Pharma Res 14 1997 522 526
57. R. Rupprecht, J.M. Reul, B. van Steensel, D. Spengler, M. Soder, B. Berning, F. Holsboer, and K. Damm Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands Eur J Pharmacol 247 1993 145 154
58. F. Le Billan, J.A. Khan, K. Lamribet, S. Viengchareun, J. Bouligand, J. Fagart, and M. Lombès Cistrome of the aldosterone-activated mineralocorticoid receptor in human renal cells FASEB J 29 2015 3977 3989
59. M.J. Kert, L.W. Tarr, S. Franklin, E. Gold, R. Okun, and M. Maxwell Experience with the use of an aldosterone antagonist in selected hypertensive patients Angiology 23 1972 617 627
60. G. Schrijver, and M.H. Weinberger Hydrochlorothiazide and spironolactone in hypertension Clin Pharmacol Therap 25 1979 33 42
61. M.H. Weinberger, B. Roniker, S.L. Krause, and R.J. Weiss Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension Am J Hypertens 15 2002 709 716
62. A. Esteghamati, S. Noshad, S. Jarrah, M. Mousavizadeh, S.H. Khoee, and M. Nakhjavani Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial Nephrol Dial Transplant 28 2013 2823 2833
63. M. Epstein, G.H. Williams, M. Weinberger, A. Lewin, S. Krause, R. Mukherjee, R. Patni, and B. Beckerman Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes Clin J Am Soc Nephrol 1 2006 940 951